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BACKGROUND: Annual updates on cancer occurrence and trends in the United States are provided through an ongoing collaboration
among the American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute
(NCI), and the North American Association of Central Cancer Registries (NAACCR). This annual report highlights the increasing bur-
den of liver and intrahepatic bile duct (liver) cancers. METHODS: Cancer incidence data were obtained from the CDC, NCI, and
NAACCR; data about cancer deaths were obtained from the CDC’s National Center for Health Statistics (NCHS). Annual percent
changes in incidence and death rates (age-adjusted to the 2000 US Standard Population) for all cancers combined and for the lead-
ing cancers among men and women were estimated by joinpoint analysis of long-term trends (incidence for 1992-2012 and mortality
for 1975-2012) and short-term trends (2008-2012). In-depth analysis of liver cancer incidence included an age-period-cohort analysis
and an incidence-based estimation of person-years of life lost because of the disease. By using NCHS multiple causes of death data,
hepatitis C virus (HCV) and liver cancer-associated death rates were examined from 1999 through 2013. RESULTS: Among men and
women of all major racial and ethnic groups, death rates continued to decline for all cancers combined and for most cancer sites; the
overall cancer death rate (for both sexes combined) decreased by 1.5% per year from 2003 to 2012. Overall, incidence rates
decreased among men and remained stable among women from 2003 to 2012. Among both men and women, deaths from liver can-
cer increased at the highest rate of all cancer sites, and liver cancer incidence rates increased sharply, second only to thyroid cancer.
Men had more than twice the incidence rate of liver cancer than women, and rates increased with age for both sexes. Among non-
Hispanic (NH) white, NH black, and Hispanic men and women, liver cancer incidence rates were higher for persons born after the
1938 to 1947 birth cohort. In contrast, there was a minimal birth cohort effect for NH Asian and Pacific Islanders (APIs). NH black men
and Hispanic men had the lowest median age at death (60 and 62 years, respectively) and the highest average person-years of life
lost per death (21 and 20 years, respectively) from liver cancer. HCV and liver cancer-associated death rates were highest among
decedents who were born during 1945 through 1965. CONCLUSIONS: Overall, cancer incidence and mortality declined among men;
and, although cancer incidence was stable among women, mortality declined. The burden of liver cancer is growing and is not equally dis-
tributed throughout the population. Efforts to vaccinate populations that are vulnerable to hepatitis B virus (HBV) infection and to iden-
tify and treat those living with HCV or HBV infection, metabolic conditions, alcoholic liver disease, or other causes of cirrhosis can be
effective in reducing the incidence and mortality of liver cancer.Cancer 2016;000:000-000.VC 2016 American Cancer Society.
KEYWORDS: cancer, incidence, liver cancer, mortality, National Program of Cancer Registries (NPCR), North American Association of
Central Cancer Registries (NAACCR), Surveillance, Epidemiology, and End Results (SEER), survival, trends, viral hepatitis.
INTRODUCTION
This marks the 18th year that the American Cancer Society (ACS), the Centers for Disease Control and Prevention
(CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries
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Commentary
(NAACCR) have collaborated to develop the Annual
Report to the Nation on the Status of Cancer.1-17 These
reports provide annual updates on cancer incidence,
deaths, and trends of the most common cancers in the
United States. In addition, each publication features an
in-depth analysis of a selected special topic. This year’s
report provides a detailed analysis of the incidence of liver
and intrahepatic bile duct (liver) cancers and rates of liver
cancer and hepatitis C virus (HCV) infection-associated
deaths.
Worldwide, liver cancer is the fifth most common
cancer among men, the ninth most common cancer
among women, and the second most common cause of
cancer death for men and women combined.18 Although
liver cancer occurs more frequently in less developed
regions of the world,18 it is still a significant health out-
come in the United States. In 2012, a total of 28,012 per-
sons in the United States (excluding Nevada) were
diagnosed with liver cancer (20,207 men and 7805
women), and 22,972 died of this disease (15,563 men and
7409 women).19 The relative 5-year survival rate for liver
cancer is 16.6% (95% confidence interval [CI], 16.3%-
16.9%).19 Forty-three percent of patients with liver cancer
are diagnosed at a localized stage, for which the 5-year rel-
ative survival rate is 30.5%.20 Those diagnosed at a re-
gional stage (27%) and a distant stage (18%) have 5-year
relative survival rates of 10.7% and 3.1%, respectively.20
Viral hepatitis is an important cause of hepatocellu-
lar carcinoma (HCC), the most common histologic type
of liver cancer. Chronic infections with hepatitis B virus
(HBV) or HCV are well documented risk factors for
HCC. Globally, it is reported that both infections con-
tribute to greater than 60% of HCC cases.21 In the
United States, it has also been reported that chronic HBV
and HCV infections are major risk factors for HCC and
are correlated with increasing trends in HCC inci-
dence.22,23 Data from national US surveys indicate that
from 850,000 to 2.2 million persons are living with
chronic HBV infection,24,25 and from 2.7 to 3.5 million
persons are living with chronic HCV infection.26,27 The
age-specific prevalence of HCV infection also suggests
that persons born during 1945 through 1965 are more
likely than other birth cohorts to be diagnosed with HCV
infection.28 In the absence of improved testing and appro-
priate treatment, HCV infections among this generation
will continue to account for a substantial proportion of
deaths from liver cancer.29 Consequently, the CDC and
the United States Preventive Services Task Force
(USPSTF) recently recommended a 1-time HCV test for
persons born during 1945 through 1965.30,31 Other
important risk factors for liver cancer include excessive
alcohol consumption, obesity, nonalcoholic fatty liver dis-
ease, rare metabolic disorders, and type 2 diabetes melli-
tus.32 In this report, we closely examine incidence and
mortality trends from liver cancer among different
groups, discuss the potential risk factors contributing to
changes in liver cancer rates, and present ongoing public
health interventions aimed at reducing the burden of liver
cancer in the United States.
MATERIALS AND METHODS
Data Sources, Codes, and Selection Criteria
Cancer incidence data
Population-based cancer incidence data were obtained
from registries that participate in the CDC’s National
Program of Cancer Registries (NPCR) and/or the NCI’s
Surveillance, Epidemiology, and End Results (SEER) pro-
gram and voluntarily submit their data to NAACCR. Par-
ticipating registries met NAACCR’s data-quality criteria
for the December 2014 submission cycle.33 Site and his-
tology were coded according to the International Classifi-
cation of Diseases for Oncology (ICD-O) edition in use
at the time of diagnosis, converted to the third edition
coding,34 and categorized according to SEER site
groups.20 Only cases defined as malignant under ICD-O-
2 and ICD-O-3 were included in this report.
Incidence rates were calculated for all sites combined,
for childhood cancers (ages 0-14 and 0-19 years), and for
the most common cancers for each of the 5 major racial
and ethnic groups (white, black, Asian and Pacific Islander
[API], American Indian/Alaska Native [AI/AN], and His-
panic). Rates for Hispanic ethnicity included individuals
from all races identified as Hispanic, except in the special
section, as noted. Rates for AI/ANs were based on cases and
deaths occurring in counties covered by the Indian Health
Service Contract Health Service Delivery Areas (CHSDA),
because it has been demonstrated that these areas have
more accurate classification of AI/AN race.10,35,36
Cancer incidence data were not available uniformly
for every calendar year, geographic area, or racial and eth-
nic group in the United States. Long-term (1992-2012)
incidence trends for all racial and ethnic groups combined
were estimated by using data from the SEER-13 registries,
which cover approximately 14% of the US population.37
Five-year (2008-2012) average annual incidence rates, 5-
year (2008-2012) and 10-year (2003-2012) incidence
trends for all racial and ethnic groups combined, and 10-
year trends for each of the 5 major racial and ethnic popu-
lations were calculated by using combined data from the
NPCR and SEER registries as submitted to NAACCR.
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Together, participating registries cover 97% (for 2008-
2012) and 92% (for 2003-2012) of the US population.
Cancer mortality data
Cause of death was based on death certificate information
reported to state vital statistics offices and compiled into a
national file for the entire United States by the CDC
National Center for Health Statistics’ (NCHS) National
Vital Statistics System.38 The underlying causes of death
were selected according to the International Classification
of Disease (ICD) codes and rules in use at the time of
death (ICD-8 through ICD-10) and categorized accord-
ing to SEER site groups to maximize comparability
between ICD and ICD-O versions.20 Death rates were
calculated for all cancer sites combined, for childhood
cancers, and the most common cancers among men and
women identified by the incidence analysis. We examined
long-term (1975-2012) mortality trends for all racial and
ethnic groups combined and 5-year (2008-2012) average
annual age-adjusted death rates and 10-year (2003-2012)
mortality trends for each of the 5 major racial and ethnic
groups.
Population data
The population estimates that were used in this report rep-
resent a modification of the intercensal and Vintage 2013
annual times series of July 1; and county population esti-
mates by age, sex, race, and Hispanic origin were produced
by the US Census Bureau’s Population Estimates Program
in collaboration with the CDC’s NCHS and with support
from the NCI.39 The estimates incorporate intercensal
(July 1, 2000-2009) and Vintage 2013 (July 1, 2010-
2013) bridged, single-race estimates that are derived from
the original multiple race categories in the 2000 and 2010
US Censuses (as specified in the 1997 Office of Manage-
ment and Budget standards for the collection of data about
race and ethnicity).40 For most states, population estimates
as of July 1 of each year were used to calculate incidence
rates, which were presumed to reflect the average popula-
tion of a defined geographic area for a calendar year; how-
ever, some adjustments were made to refine these
estimates, as has been done in previous reports.16,17,39
Liver and Intrahepatic Bile Duct Cancer-Specific
Incidence and Mortality Data
The special analysis for this report included all invasive
liver and intrahepatic bile duct (liver) cancer cases (ICD-
O-3 site codes C220 and C221, excluding histology codes
9050-9055; 9140; 9590-9989). Analyses in this section
were restricted to 4 large, nonoverlapping racial or ethnic
groups with a sufficient number of cases to produce in-
formative results: non-Hispanic (NH) white, NH black,
NH API, and Hispanic. Small counts produced unstable
rate estimates for the NH AI/AN group and have been
excluded from certain analyses.
To help understand differences in liver cancer inci-
dence rates and trends by birth cohort, we conducted age-
period-cohort analyses. We grouped liver cancer inci-
dence data from the SEER-13 registries into 5-year age
groups (ages 35-39 through 80-84 years) and 5-year cal-
endar periods (1993-1997, 1998-2002, 2003-2007, and
2008-2012), spanning 13 partially overlapping, 10-year
birth cohorts (from 1908-1917 [referred to as “1913,”
the mid-year of birth] through 1968-1977). To analyze
age-specific liver cancer incidence rates by period, data
from the SEER-13 registries were grouped into 5-year
age groups (35-39 through 80-84 and 85 years) and 5-
year periods (1992-1996, 2000-2004, and 2008-2012),
which were the beginning, middle, and end of the 20-
year span.
To examine the distribution of liver cancer deaths by
race and ethnicity, SEER-18 incidence-based mortality
data for liver cancer deaths (ICD-10 codes C22) during
2008 through 2012 were analyzed. All patients in this
analysis were diagnosed with and subsequently died of
liver cancer, lessening the misclassification of death from
liver cancer metastasis as death from primary liver cancer.
Patients who had death certificate and autopsy-only diag-
noses were excluded. SEER-18 registries cover 28% of the
US population.
Because HCV infection is a major contributing fac-
tor for HCC in the United States, we also examined
HCV and liver cancer-associated mortality for 1999
through 2013. The cancer mortality data and population
files used in this analysis were consistent with the files
used for other cancer mortality estimates in this report.
The data were analyzed to describe mortality by birth
year category and year of death and by birth year category
and age at death for decedents aged 35 years who had
both HCV and liver cancer listed among causes of death.
Birth year and cohort were assigned by subtracting the
age at death from the year of death. The underlying cause
of death and multiple causes of death were selected
according to ICD-10 codes41 and selection rules in use at
the time of death.42 HCV and liver cancer-associated
deaths were defined as having HCV (ICD-10 codes
B17.1 or B18.2) and liver cancer (ICD-10 codes C22.0-
C22.9) listed together anywhere on the death record as ei-
ther the underlying cause or among the multiple causes of
death.
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Statistical Methods
Incidence and death rates and trends
Age-adjusted rates were expressed per 100,000 persons on
the basis of the 2000 US Standard Population and were
generated by using SEER*Stat software, version 8.2.1.43
Corresponding 95% CIs were calculated as modified c
intervals.44 For stability and reliability, incidence rates
were suppressed if there were fewer than 16 cases for the
time interval, and incidence trends were suppressed if
there were fewer than 10 cases for at least a year within the
time interval. Death rates were suppressed if there were
fewer than 10 deaths.
Trends in age-adjusted cancer incidence and death
rates were estimated using joinpoint regression.45,46 Up to
5 joinpoints were allowed in models for 1975 to 2012, up
to 3 joinpoints were allowed in models for 1992 to 2012,
and up to 2 joinpoints were allowed in models for 2003 to
2012. The resulting trends were described according to
the annual percent change (APC). The average APC
(AAPC) was estimated as a weighted geometric average of
the APCs, with the weights equal to the length of each line
segment during the prespecified, fixed interval.47 Long-
term incidence trends were calculated by using both
observed and delay-adjusted SEER-13 data.48 Descrip-
tions of the long-term incidence trends were based on the
delay-adjusted data unless otherwise noted. Delay-
adjustment factors are not currently published for NPCR;
thus, all 5-year and 10-year trends were based on observed
NPCR and SEER combined data without delay adjust-
ment. We used the t test and the Z test, respectively, to
test whether the APC and AAPC were statistically differ-
ent from zero. All statistical tests were 2-sided. In describ-
ing trends, the term increase or decrease was used when the
slope of the trend (APC or AAPC) was statistically signifi-
cant (2-sided P < .05). For nonstatistically significant
trends, terms such as stable, nonsignificant increase, and
nonsignificant decrease were used.
Liver Cancer Age-Period-Cohort and Estimated
Years-of-Life-Lost Analysis
Liver cancer incidence rates were examined by sex, age,
race or ethnicity, state, and year of diagnosis by using the
same methods described above. The NCI’s online age-
period-cohort analysis tool was used to calculate cohort
rate ratios, comparing liver cancer incidence rates in each
birth cohort relative to the 1943 birth cohort, and adjust-
ing for age and period effects.49 The 1943 birth cohort
was selected as the reference because it immediately pre-
ceded the known increase in the prevalence of HCV infec-
tion for individuals born during 1945 through 1965.28
Proportions of incidence-based deaths from liver
cancer and median age at death were determined by sex
and race or ethnicity.50 Person-years of life lost (PYLL) to
liver cancer were calculated by linking the “expectation of
life at age x” column of the US 2010 complete life tables
to single-year age-at-death data.20,51,52 All-race life tables
were used to calculate overall PYLL, whereas single-sex,
all-race tables were used for gender-specific analyses. The
average PYLL (APYLL) per death was calculated as the
PYLL divided by the number of deaths.
HCV and liver cancer-associated death rates during
1999 through 2013 for those aged35 years according to
3 birth-year categories (those born before 1945, during
1945-1965, and during 1966-1978) were examined by
year at death. To remove the effect of age, HCV and liver
cancer-associated death rates also were examined using
slightly more refined birth-year categories (those born
before 1945, during 1945-1949, during 1950-1959, dur-
ing 1960-1965, and during 1966-1978) and by age at
death. Crude HCV and liver cancer-associated death rates
were calculated by dividing the number of deaths in each
category by the US Census population estimate for each
year. A similar methodology was applied in a previous
study that examined the burden of mortality associated
with viral hepatitis in the United States from 1999 to
2007.53
RESULTS
Long-Term Trends of Cancer Incidence Rates for
the Most Common Cancers
Trends in delay-adjusted cancer incidence rates using data
from SEER-13 registries that submitted data to the NCI
from 1992 to 2012 are presented in Table 1. Cancer inci-
dence rates decreased among men during each period, but
at different rates. In contrast, cancer incidence rates
among women increased slightly (0.8% per year) from
1992 to 1998, then remained stable. Among children in
both age groups, (ages 0-14 and 0-19 years), incidence
rates increased from 1992 to 2012 with an APC of 0.8%.
During 2003 through 2012, the AAPC indicated
that overall cancer incidence rates for all persons com-
bined decreased on average 0.7% per year (Table 1).
Among men, overall cancer incidence decreased on aver-
age by 1.4% per year during 2003 through 2012; how-
ever, among women, rates were stable during this 10-year
period. Among men, incidence rates for 7 of the 17 most
common cancers decreased from 2003 to 2012 (prostate,
colon and rectum [colorectal], lung and bronchus [lung],
stomach, larynx, urinary bladder [bladder], and brain and
other nervous system [brain]). The most striking decline
Commentary
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was for prostate cancer, which had an average 6.6%
decline per year for the most recent 5-year period (2008-
2012). In contrast, incidence rates increased among men
during 2003 through 2012 for 8 cancers (thyroid, liver,
myeloma, melanoma of the skin [melanoma], kidney and
renal pelvis [kidney], leukemia, pancreas, and oral cavity
and pharynx). Among women, incidence rates for 6 of the
18 most common cancers decreased during 2003 through
2012 (colorectal, cervix uteri [cervix], lung, bladder,
ovary, and stomach), whereas incidence rates among
women increased during 2003 through 2012 for 8 cancers
(thyroid; liver; corpus and uterus, not otherwise specified
[uterus]; kidney; pancreas; melanoma; leukemia; and my-
eloma). Incidence rates were stable for all other sites.
Long-Term Trends of Cancer Death Rates for
the Most Common Cancers
The long-term (1975-2012) mortality trend analysis
revealed that the overall cancer death rate in the United
States has generally declined since the early 1990s for
adults and since the 1970s for children (Table 2). More
recently, from 2003 to 2012, death rates continued to
decline by an average of 1.5% per year overall, by 1.3%
per year for children ages 0 to 14 years, and by 2.0% per
year for children ages 0 to 19 years. Among men, death
rates declined overall from 2003 to 2012 (1.8% per year).
Relatively large declines among men were also observed
for cancers of the prostate (3.5% per year), stomach
(3.3% per year), colorectum (2.9% per year), lung (2.7%
per year), and larynx (2.5% per year) and for non-
Hodgkin lymphoma (2.2% per year). Declines in death
rates during this time among men were 1% per year for
leukemia, myeloma, and cancers of the esophagus and
kidney. Death rates among men remained stable during
this time for melanoma and for cancers of the bladder,
brain, and oral cavity and pharynx. Death rates increased
among men during 2003 through 2012 for cancers of the
liver (2.8% per year); soft tissue, including the heart
(1.1% per year); and pancreas (0.3% per year).
Among women, during 2003 through 2012, death
rates declined overall (1.4% per year) and for non-
Hodgkin lymphoma (3.1% per year), colorectal cancer
(2.9% per year), leukemia (1.2% per year), and myeloma
(1.2% per year), and for cancers of the stomach (2.6% per
year), ovary (2.0% per year), breast (1.9% per year), lung
(1.4% per year), oral cavity and pharynx (1.3% per year),
gallbladder (1.2% per year), kidney (1.0% per year), cer-
vix (0.9% per year), and bladder (0.4% per year), and
remained stable for brain cancer, but increased for cancers
of the liver (2.2% per year), uterus (1.1% per year), and
pancreas (0.4% per year).
Current Cancer Incidence Rates and Trends by
Race and Ethnicity
By using data from both SEER and NPCR registries, 5-
year (2008-2012) average annual incidence rates and 5-
year (2008-2012) and 10-year (2003-2012) incidence
trends were analyzed by site, sex, and race and ethnicity
(Table 3). During 2008 through 2012, observed rates of
all cancers combined in all racial groups were lower
among women than among men (412.6 vs 512.7 per
100,000). Black men had the highest overall cancer inci-
dence rate (573.6 per 100,000) of any racial or ethnic
group, and non-Hispanics had higher rates than His-
panics (464.7 vs 353.7 per 100,000). Among women,
white women had the highest overall cancer incidence rate
during this time of any racial or ethnic group (418.4 per
100,000). Prostate cancer remained the most common
cancer among men in each racial and ethnic group, and
the rates were substantially higher than for any other type
of cancer. Lung and colorectal cancer were the second and
third most common cancers, respectively, among men of
all racial and ethnic groups, except among Hispanic men,
in whom these ranks were reversed. Breast cancer was the
most common cancer among women of all racial and eth-
nic groups. Like in men, lung cancer was the second most
common cancer among women, followed by colorectal
cancer, except among API and Hispanic women, in
whom the ranks were reversed. Rankings of other cancers
for both men and women varied by race and ethnicity.
White children had higher cancer incidence rates than
children of other racial and ethnic groups.
Overall cancer incidence rates among men declined
in each racial and ethnic group during 2003 through
2012. During 2003 through 2012, the incidence rates for
the 4 most common cancers among men decreased (pros-
tate, lung, colorectal, and bladder) for all races except
among black men, for whom bladder cancer incidence
rates remained stable. Thyroid cancer incidence rates
among men increased >5% annually during 2003
through 2012 for all racial and ethnic groups except for
AI/AN, for whom the increase was not statistically signifi-
cant. Trends in incidence rates for most cancers among
men in each racial and ethnic group were similar in direc-
tion to those of all men combined, but some trends were
not statistically significant. Oral cancer incidence rates
decreased among black men (22.5% per year), and liver
cancer incidence rates decreased among API (21.3% per
Report on Status of Cancer, 1975-2012/Ryerson et al
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year), but they increased or remained stable among other
racial and ethnic groups.
Among women, the overall cancer incidence rates
declined slightly from 2003 to 2012 for women in all
racial and ethnic groups combined, but this decline was
not statistically significant for most racial and ethnic
groups. Whereas breast cancer incidence rates remained
stable during this period for women overall, rates
increased among black women (0.8% per year) and API
women (1.1% per year). During 2003 through 2012,
lung cancer incidence rates decreased among women of all
racial and ethnic groups, except API and AI/AN. Colo-
rectal cancer incidence rates decreased among women of
all racial and ethnic groups; thyroid cancer incidence rates
increased among women of all groups; and uterus cancer
incidence rates increased among women of all groups,
except AI/AN. Like in men, trends in incidence rates dur-
ing the past decade for most cancers in each racial and eth-
nic group were similar in direction to those for all women
combined, but some trends were not statistically signifi-
cant. Oral cancer incidence rates decreased among black
women but increased or remained stable among most
racial and ethnic groups, and melanoma incidence rates
increased among white women but decreased among His-
panic women.
Current Cancer Death Rates and Trends by Race
and Ethnicity
Five-year (2008-2012) death rates and fixed-interval mor-
tality trends from 2003 to 2012 were analyzed by sex and
by race and ethnicity (Table 4). For all cancer sites com-
bined, cancer death rates (per 100,000) for 2008 to 2012
were higher among men than among women (207.9 vs
145.4). During 2008 through 2012, black men and
Figure 1. Age-adjusted incidence rates for 2008 to 2012 of liver and intrahepatic bile duct cancer are illustrated by state for areas
in the United States with high-quality incidence data. Rates are per 100,000 persons and were age-adjusted to the 2000 US
standard population (19 age groups: ages <1 year, 1-4 years, 5-9 years, . . ., 80-84 years, 85 years [Census publication p25-1130;
US Bureau of the Census, Current Population Reports, p25-1130. Washington, DC: US Government Printing Office; 2000]). Source:
National Program of Cancer Registries and Surveillance, Epidemiology, and End Results areas reported by the North American
Association of Central Cancer Registries as meeting high-quality incidence data standards for the specified time. Rates from
2008 to 2012 for non-Hispanic (NH) whites, NH blacks, NH American Indians/Alaska Natives (Contract Health Services Delivery
Area 2012 counties), NH Asians/Pacific Islanders, and Hispanics (48 states: Alabama, Alaska, Arizona, California, Colorado, Con-
necticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine,
Maryland, Massachusetts, Michigan, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New Mexico, New
York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennes-
see, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming).
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women had the highest cancer death rates compared with
all other racial and ethnic groups. Lung cancer was the
leading cause of cancer death among both men and
women of all racial and ethnic groups, except among His-
panic women, for whom mortality from breast cancer was
higher. Among men, lung cancer was followed by prostate
cancer and then colorectal cancer as the leading causes of
cancer death, except among API men, for whom liver can-
cer replaced prostate cancer as the second leading cause of
cancer death. Among women of all racial and ethnic
groups, except Hispanic women, lung cancer was followed
by breast and colorectal cancers as the leading causes of
cancer death; among Hispanic women, breast cancer mor-
tality was followed by lung cancer and colorectal cancer
mortality.
From 2003 to 2012, death rates declined for the most
common cancers (lung, prostate, colorectal, breast) among
men and women of all racial and ethnic groups except for
statistically insignificant decreases in lung cancer and colo-
rectal cancer among AI/AN men and in colorectal cancer
among AI/AN women. Death rates for most cancer sites
declined or were stable from 2003 to 2012 among men and
women of each racial and ethnic group, except for liver can-
cer, which increased for most racial and ethnic groups
except for API men and women and AI/AN women; pan-
creatic cancer, which increased among white men and
women and API women; soft tissue cancer, which increased
among white and Hispanic men; uterine cancer, which
increased among white, black, API, and Hispanic women;
and leukemia, which increased among API women.
Incidence of Liver Cancer
Rates of incident liver and intrahepatic bile duct (liver)
cancer were examined by mutually exclusive racial or eth-
nic groups, gender, and age during 2008 through 2012 to
better describe demographic patterns (Table 5). Among
men and women, liver cancer incidence rates were highest
among NH AI/ANs, followed by NH APIs, and His-
panics. Among all racial or ethnic groups, liver cancer
incidence rates among men were more than twice those
among women. Among men, liver cancer incidence rates
increased during 2008 through 2012 among NH white,
NH black, and NH AI/AN men, but decreased among
NH API men, and were stable among Hispanic men. A
different pattern emerged for liver cancer incidence rates
among women, which increased among Hispanic women
Figure 2. Age-specific incidence rates from 2008 to 2012 of liver and intrahepatic bile duct cancer are illustrated by race or eth-
nicity for areas in the United States with high-quality incidence data. Rates are per 100,000 persons and were age-adjusted to
the 2000 US standard population (19 age groups: ages <1 year, 14 years, 5-9 years, . . ., 80-84 years, 85 years [Census publica-
tion p25-1130; US Bureau of the Census, Current Population Reports, p25-1130. Washington, DC: US Government Printing Office;
2000]). Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results areas reported by the
North American Association of Central Cancer Registries as meeting high-quality incidence data standards for the specified time.
Rates from 2008 to 2012 for non-Hispanic (NH) whites, NH blacks, NH American Indians/Alaska Natives (AI/AN) (Contract Serv-
ices Delivery Area [CHSDA] 2012 counties), NH Asians/Pacific Islanders (API), and Hispanics (48 states: Alabama, Alaska, Ari-
zona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa,
Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, Montana, Nebraska, New Hampshire,
New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South
Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming).
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and among NH white and NH black women. Among
both men and women, liver cancer incidence rates
increased significantly from 2008 to 2012, beginning at
age 55 years, and the largest AAPC was observed among
the group ages 60 to 64 years among men and the group
ages 55 to 59 years among women. Liver cancer incidence
rates among both men and women increased with age for
almost all groups until age 85 years. State-specific liver
cancer incidence rates ranged 3-fold, from 3.3 to 12.5 per
100,000 persons (Fig. 1). Liver cancer incidence rates
were highest in Pacific states, in states on the southern US
border, in the District of Columbia, and in a few states in
the Northeast, including Delaware, Connecticut, Massa-
chusetts, and New York.
The age distribution of liver cancer diagnosed dur-
ing 2008 through 2012 varied across racial or ethnic
groups (Fig. 2). Although liver cancer incidence rates gen-
erally increased with age, the rate of increase varied by
racial or ethnic group. Furthermore, liver cancer incidence
rates during 2008 through 2012 among NH blacks
peaked at an earlier age (60-64 years), and then decreased
at older ages. The NH AI/AN population also had an
increase at younger ages (ages 55-59 years); however, liver
cancer incidence rates continued to increase among this
group up to ages 80 to 84 years. The statistical uncertainty
in the liver cancer incidence rates by age group among the
NH AI/AN population was mostly caused by the smaller
number of cases at each age, as indicated in the Figure 2
inset. Because of this statistical instability, the incidence
rates for NH AI/AN populations are not provided sepa-
rately in later analyses. NH API populations experienced
the highest liver cancer incidence rates for those aged<50
years and 65 years (after NH AI/AN populations), but
Hispanic and NH blacks had higher rates in the group
ages 50 to 64 years. The lowest liver cancer incidence rates
for each age group were observed among NH white
populations.
Figure 3 illustrates the cohort rate ratios and 95%
CIs by race or ethnicity for liver cancer incidence relative
to the experience of the 1943 reference birth cohort.
Among NH white, NH black, and Hispanic men and
women, the cohort rate ratio was <1.0 for the 1913 to
1938 birth cohorts. The rate ratio then sharply increased
for birth cohorts 1948 through 1953. The rate ratio for
birth cohorts 1953 through 1968 slightly decreased
among NH whites and Hispanics but decreased sharply
among NH blacks. In contrast, the cohort relative risk
remained unchanged for NH APIs, signifying a minimal
birth-cohort effect.
Figure 4 illustrates liver cancer incidence rates by age
for cases diagnosed during 3 time intervals: 1992 to 1996,
2000 to 2004, and 2008 to 2012. Liver cancer incidence
rates in general, as noted above, continued to increase
with advancing age for each diagnosis period. However,
during 2008 through 2012, liver cancer incidence rates
among NH blacks were highest among persons ages 55 to
59 years, who are in the 1953 birth cohort (born during
1948-1957). A similar pattern is observed among NH
whites and Hispanics, for whom there was a sharp increase
among those ages 55 to 59 years during 2008 through
2012, although liver cancer incidence rates continued to
increase with age. Among NH whites, NH blacks, and
Hispanics, liver cancer incidence rates were generally
highest for the most recent (2008-2012) diagnosis years
and lowest for the 1992 to 1996 diagnosis years. Among
Hispanics, there was a large difference between diagnosis
years for every age; whereas, among NH whites and NH
blacks, the largest difference was for those ages 50 to 69
years. The differences by diagnosis year were less pro-
nounced among NHAPIs than among other subgroups.
Table 6 presents incidence-based mortality data for
liver cancer in the SEER-18 areas during 2008 through
2012. More than half of these deaths (53%) occurred
among NH whites. The median age at death from liver
cancer was younger among NH blacks (median age, 61
years) and Hispanics (median age, 64 years) than among
NH whites (median age, 66 years) and NH APIs (median
age, 68 years). The median age at death was 9 years older
among women (median age, 72 years) than among men
(median age, 63 years), but this difference ranged from 4
years among NH blacks to 10 years among NH APIs.
More than 379,000 person-years of life were lost to liver
cancer during 2008 through 2012. The average person-
years of life that were lost to liver cancer death was higher
among NH blacks (average, 22 PYLL) and Hispanics (av-
erage, 20 PYLL) than among NH APIs and NH whites
(average, 18 PYLL for both). Although 74% of total
PYLL were among men, the APYLL was similar among
men (19 APYLL) and women (17 APYLL).
HCV and liver cancer-associated mortality from
1999 to 2013 is illustrated in Figure 5. Among persons
for whom both HCV and liver cancer were listed as
causes of death, those born during 1945 through 1965
had the largest increase in mortality from 1999 to 2013
relative to the other birth-year categories (Fig. 5A). Con-
sidering the differences in age between birth cohorts,
those born during 1945 through 1965 had substantially
higher rates of HCV and liver cancer-associated deaths
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Figure 4. Age-specific liver and intrahepatic bile duct cancer
incidence rates are illustrated by race or ethnicity and by age
and year of diagnosis in the Surveillance, Epidemiology, and
End Results (SEER)-13 areas from 1992 to 2012. Rates are per
100,000 persons. API indicates Asian/Pacific Islander. Source:
SEER-13 areas covering about 14% of the US population (Con-
necticut, Hawaii, Iowa, Utah, and New Mexico; the Alaska
Native Tumor Registry; rural Georgia; and the metropolitan
areas of San Francisco, Los Angeles, San Jose-Monterey,
Detroit, Atlanta, and Seattle-Puget Sound).
Figure 3. Cohort rate ratios (horizontal blue lines) and 95%
confidence intervals (blue shading) are illustrated for the inci-
dence of liver and intrahepatic bile duct cancer by race or
ethnicity relative to the experience of the 1943 reference
birth cohort (Surveillance, Epidemiology, and End Results
[SEER]-13 areas, 1992-2012). The vertical lines indicate a rate
ratio of 1 (no difference between a select birth cohort and
the reference cohort). API indicates Asian/Pacific Islander.
Source: SEER-13 areas covering about 14% of the US popula-
tion (Connecticut, Hawaii, Iowa, Utah, and New Mexico; the
Alaska Native Tumor Registry; rural Georgia; and the metro-
politan areas of San Francisco, Los Angeles, San Jose-
Monterey, Detroit, Atlanta, and Seattle-Puget Sound).
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than the preceding or subsequent birth cohorts, particu-
larly for the mid-generational group (Fig. 5B).
DISCUSSION
Ongoing reductions in both the incidence and mortality
of cancer overall, and specifically deaths from the most
common cancers (female breast, prostate, lung, and colo-
rectal cancers) in most racial and ethnic groups, represent
continued progress in specific areas of public health and
oncology care.2-17 For example, successful and compre-
hensive public health tobacco-control strategies remain an
important contributing factor to the observed declines in
lung cancer incidence and mortality among both men and
women.11,54-56 To aid in the earlier diagnosis of lung
cancer among those who remain at an increased risk from
tobacco use, in 2013, the USPSTF recommended routine
screening with low-dose computed tomography of per-
sons at high-risk because of their age and cigarette smok-
ing history.57 Continuing public health surveillance is
needed to monitor the success of these efforts to increase
screening in appropriate populations; and resulting reduc-
tions in mortality may reflect a decrease in lung cancer
mortality rates.
Colorectal cancer incidence and death rates also con-
tinue to decline. There is strong evidence to support the
finding that screening for colorectal cancer reduces both
the incidence and the mortality of the disease,58 and
increases in colorectal cancer survival rates during the past
2 decades have been attributed largely to screening.59-61
Still, a recent report about the use of colorectal cancer
screening indicated that 35% of US adults were not up to
date with one of the colorectal cancer screening tests rec-
ommended by the USPSTF.62 To help increase colorectal
cancer screening compliance, the CDC funds the Colo-
rectal Cancer Control Program to implement evidence-
based interventions and provide screening and follow-up
services for a limited number of eligible individuals.63 In
addition, in 2014, the National Colorectal Cancer
Roundtable, a coalition aimed at reducing colorectal can-
cer incidence and mortality, initiated a nationwide goal of
increasing colorectal cancer screening prevalence to 80%
by 2018.64
Breast cancer, as the most commonly diagnosed and
second leading cause of cancer death among women,
remains an important public health issue. Advances in
treatment and early detection contribute to the ongoing
decrease in breast cancer mortality among women over-
all.65 However, not all racial and ethnic groups benefit
equally in this favorable trend: black women have a higher
breast cancer death rate than white women.17 Efforts are
underway to better understand the factors contributing to
these observed differences, including surveillance of breast
TABLE 6. Distribution of Deaths, Median Age at Death, and Person-Years of Life Lost From Liver and Intra-
hepatic Bile Duct Cancer, by Sex, and Race or Ethnicity, Surveillance, Epidemiology, and End Results-18
Areas, 2008 to 2012a
Sex, Race, and
Ethnicityb
Deaths by
Race, %c
Deaths by
Sex, %c
Median Age
at Death, y
Total No.
of PYLLd
PYLL by
Race, %d
PYLL by
Sex, %d
Average PYLL
per Deathd
Total 100 65 379,464 100 19
Men 73 63 270,741 74 19
Women 27 72 93,294 26 17
Non-Hispanic, white 53 66 192,278 51 18
Men 73 64 137,046 74 18
Women 27 73 47,180 26 17
Non-Hispanic, black 13 61 55,030 15 22
Men 76 60 40,038 76 21
Women 24 64 12,733 24 21
Non-Hispanic, API 15 68 56,248 15 18
Men 69 65 39,543 73 19
Women 31 75 14,570 27 16
Hispanic 18 64 70,588 19 20
Men 73 62 50,486 74 20
Women 27 71 17,308 26 18
Abbreviations: API, Asian/Pacific Islander; PYLL, person-years of life lost.
a Source: Surveillance, Epidemiology, and End Results (SEER)-18 areas covering about 28% of the US population (10 state registries [Connecticut, Georgia,
Greater California, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, and Utah], 3 Native American registries [the Alaska Native Tumor Registry, Ari-
zona Indians, and the Cherokee Nation Cancer Registry], and 5 metropolitan area registries [metropolitan Atlanta and rural Georgia, San Francisco-Oakland
and San Jose-Monterey, Los Angeles, Detroit, and Seattle-Puget Sound]).
b The table excludes individuals of unknown Hispanic and Hispanic other/unknown race.
c Values indicate incidence-based mortality.
d PYLL and average PYLL estimates are 5-year totals estimated by using overall, male, and female all-races life tables.
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cancer subtypes by different racial and ethnic groups,17
and to promote the use of evidence-based interventions
aimed at groups struggling with access to care, such as
CDC’s National Breast and Cervical Cancer Early Detec-
tion Program.66
The continued decrease in prostate cancer incidence
likely reflects the continued reduction in the use of
prostate-specific antigen testing.67-70 In 2008, the
USPSTF concluded that there was insufficient evidence to
recommend prostate cancer screening among men aged
75 years; and, in 2012, it further recommended against
screening for all men,71 likely contributing to the observed
reduction in incidence rates since that time.15-17,72 Close
public health surveillance of both prostate stage-specific
incidence and death rates will be particularly important
during future years to ensure a balance is achieved between
reducing unnecessary screening and ensuring appropriate
and early diagnosis and treatment of more aggressive cases
of this important cancer among men.
Despite the successful reductions in the occurrence
of and deaths from the most common cancers, several can-
cer sites show unfavorable trends, particularly liver cancer.
Liver cancer death rates are increasing at the highest rate
of all cancer sites among both men and women. Indeed,
the incidence of liver cancer is also increasing at rates sec-
ond only to those of thyroid cancer. The differences in
liver cancer incidence observed by sex, race or ethnicity,
and birth cohort highlighted in this annual report suggest
differences in the distribution of a variety of risk factors
among different groups and over time.
HCC is the most common histologic type of pri-
mary liver cancer, and HCC trends are largely affected by
the changing prevalence of risk factors. In the United
States, a critical risk factor is HCV infection.73 Risks for
HCV transmission are primarily associated with paren-
teral exposures, including receipt of contaminated blood
and injection drug use. The incidence of HCV infection
was highest during the 1960s to 1980s, before the virus
was discovered and preventive measures, including HCV
screening of the blood supply, became possible. Conse-
quently, the prevalence of HCV infection is particularly
high among individuals born during 1945 through
1965.28,74,75 Thus, in 2012, the CDC recommended 1-
time HCV testing for individuals born during 1945
through 1965 (ages 47-67 years in 2012).31 The following
year, the USPSTF issued similar recommendations.76
Figure 5. Crude death rates associated with hepatitis C virus and liver or intrahepatic bile duct cancer are illustrated among
decedents aged 35 years according to (A) birth cohort and year and (B) birth cohort and age for the United States from 1999
to 2013. Rates are per 100,000 persons. Hepatitis C virus was defined according to the International Classification of Diseases
10th Revision (ICD-10) codes B17.1 and B18.2. Liver and intrahepatic bile duct cancers were defined by any ICD-10 code in the C22
ICD-10 category. Patients who died from liver or intrahepatic bile duct cancers had hepatitis C and liver or intrahepatic bile duct
cancer listed together as any cause of death on their death certificate. Source: National Center for Health Statistics public-use
data file for the total United States, 1999 to 2013.
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This annual report provides evidence of an increased bur-
den of HCV and liver cancer-associated mortality among
this birth cohort; although, according to the 2013
National Health Interview Survey, only 12.3% of persons
born during 1945 through 1965 reported HCV testing.77
Increased liver cancer incidence among this birth cohort is
particularly elevated for NH whites, NH blacks, and His-
panics. Findings of a high burden of HCC among certain
racial or ethnic groups is consistent with race-specific
HCV infection prevalence estimates fromUS surveys.78
Among APIs, HBV is the dominant HCC-related
virus, particularly among those not born in the United
States.79 Because hepatitis B vaccination of infants is now
widespread, the prevalence of HBV infection is declining
in most Asian countries among vaccinated cohorts of chil-
dren and adolescents.80,81 Accordingly, hepatitis B vacci-
nation is considered a best buy for liver cancer
prevention.82 Consequently, HBV-related HCC among
APIs may decline in coming generations. However, in the
immediate term, HBV infection prevalence remains high
among unvaccinated adults from these countries, repre-
senting an ongoing risk of liver cancer.83 HBV testing fol-
lowed by HBV therapy is associated with a reduction
from 50% to 80% in the risk of liver cancer.84,85 In 2008,
the CDC recommended HBV testing for persons born in
sub-Saharan Africa, Asia, and countries in other world
regions where HBV infection prevalence is 2%. In
2014, the USPSTF also recommended HBV testing for
these target populations.86
Cirrhosis is a precursor for most liver cancers.
Screening of individuals at risk of cirrhosis increases the
chance of detecting liver cancer at an early stage when it is
more amenable to therapy. Population groups at risk of
cirrhosis include persons with metabolic disease, history
of liver disease, history of heavy alcohol use, exposure to
HCV or HBV, and some rare genetic disorders.87 Increas-
ing evidence suggests that other risk factors, such as type 2
diabetes mellitus and metabolic syndrome (ie, clustering
of at least 3 of the following: obesity, elevated blood
pressure, elevated fasting plasma glucose, high serum tri-
glycerides, and low high-density lipoprotein levels), are
also important contributing factors, particularly when
considering the prevalence of these types of medical con-
ditions among the population by using the calculation of
a population-attributable fraction (PAF).32 A recent
SEER-Medicare analysis of HCC cases diagnosed during
1994 through 2007 among persons aged68 years exam-
ined odds ratios (ORs) as well as PAFs for the most com-
mon risk factors for HCC.32 Among this study
population, the strongest predictors of HCC were HCV
infection (OR, 39.9), HBV infection (OR, 11.2),
alcohol-related disease (OR, 4.1), metabolic disease (OR,
3.5), and diabetes and/or obesity (OR, 2.3). However,
when the prevalence of each risk factor was considered, di-
abetes and/or obesity had the highest PAF (36.6%), fol-
lowed by alcohol-related disease (PAF, 23.5%), HCV
infection (PAF, 22.4%), HBV infection (PAF, 6.3%),
and metabolic disease (PAF, 3.2%).
Although there are a variety of risk factors for liver
cancer, approximately 22% of HCC among those aged
65 years in the United States is attributed to HCV,32
and an estimated 1.6 million persons will be eligible for
HCV treatment by 2020.88 Previous interferon-based
therapies are associated with considerable toxicity,89 yet
current standards of HCV treatment include from 8 to 12
weeks of all-oral medications with fewer side effects,
which can produce a sustained virologic response in
>85% of HCV-infected individuals who complete treat-
ment.90-92 It is estimated that, compared with interferon-
based therapy, newer antiviral therapies, such as
sofosbuvir-ledipasvir, could prevent an additional 310
cases of HCC per 10,000 treated HCV cases. However,
fewer than half of persons living with HCV are aware of
their infection; and, among those who know their status,
many do not receive appropriate clinical management of
HCV infection and associated liver disease.93 Although
drug expenditures for treatment of HCV infection have
declined as a result of mandated rebates for Medicaid and
privately negotiated prices by health plans, the cost of
HCV medications may limit the number of patients
receiving recommended antiviral therapy.94 Barriers to
HCV testing and access to adequate care with affordable
medications must be overcome to prevent HCV-related
liver cancer.95
The burden of liver cancer is not equally distributed
across the US population, reflecting the heterogeneous
prevalence of liver cancer risk factors among groups. Men
have nearly a 3-fold higher rate of liver cancer incidence
than women. Liver cancer incidence rates generally
increase with age. Historically, APIs have been the racial
group most affected by liver cancer; however, that may
change if the decreasing trend in this group continues as
trends increase for other racial groups. Indeed, our analy-
sis indicates that, among individuals ages 55 to 64 years,
NH blacks and Hispanics had higher rates than APIs. NH
black and Hispanic men have the youngest median age at
liver cancer death and the highest APYLL to liver cancer.
Although NH whites have lower liver cancer rates than
other racial or ethnic groups, they make up a large
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segment of the US population and account for the major-
ity of deaths and PYLL to liver cancer in the United
States.
Limitations
The completeness, quality, and geographic coverage of
cancer incidence data exceed those available for other
chronic diseases. The NPCR and SEER data set used for
general trends is the most complete and current data set
available, covering the vast majority of the US population.
However, as with any surveillance data set, local level varia-
tions in data quality, incomplete geographic or population
reporting, and the complexity of estimating the underlying
populations at risk may have influenced the results
reported here. For instance, reporting from smaller hospi-
tals or providers unaffiliated with a cancer center may be
less complete or may have a longer lag in reporting time.
Corrections for late reporting were incorporated into the
rates and trends that included delay adjustment; however,
this adjustment was not possible for data used to estimate
race-specific or ethnicity-specific incidence trends, and dif-
fering results may occur, particularly for sites typically
diagnosed in a physician’s office, like melanoma.
Another issue is the compatibility of the cancer data
and the population data by race. Since 2000, the US Cen-
sus has provided the opportunity for respondents to self-
select multiple race categories, which has created incom-
patibility between the classification of race in the popula-
tion denominators from the Census (self-reported) with
the incidence numerators from registry data (from medical
record) and the mortality numerators from the National
Vital Statistics System (recorded by medical examiner).
The methods for developing single-race estimates from
these data are complex and can create additional uncertain-
ties in racial estimates and resultant rates.96,97 The broad
Hispanic and API categories may mask important epide-
miologic variation in risk by country of origin.98,99
We present rates by race separately from Hispanic
ethnicity for the cancer incidence and mortality section
(Tables 1–4), so the race categories include Hispanics.
Thus, as the proportion of the Hispanic population in the
United States increases over time, this may influence the
reported trends. Shifts in demographics can influence sur-
veillance trends, and our results must be interpreted with
this in mind. Furthermore, death rates for the AI/AN,
API, and Hispanic populations may be underestimated
because of reporting problems on the death certificate and
should be interpreted with caution.100
Long-term trends were reported on the basis of
SEER-13 registries, which represent only 14% of the US
population, and the liver cancer incidence-based mortality
analysis was based on SEER-18 registries, which represent
approximately 28% of the US population. Thus, these
analyses may be influenced by the population composi-
tion of the SEER areas. More geographic population cov-
erage was available for 5-year and 10-year trends using the
combined NPCR and SEER data; however, because of
data quality concerns, data from 5 states were excluded
from 10-year trends (resulting in 92% coverage), and data
from 2 states were excluded for 5-year trends (resulting in
97% coverage), which may influence reported trends.
However, >90% of the United States was represented;
therefore, these exclusions likely have only a minor effect
on national trends.
The limitations of mortality data include the incom-
plete ascertainment of cases, misclassification, andmissing
causes of death.101,102 However, these biases may be miti-
gated by analyzing trends in which the problems have
been assumed to be relatively constant over time.53,103
Finally, despite using the largest national data set available
for cancer rates, small numbers for less common sites were
an issue for the smaller racial categories, especially AI/AN.
Small numbers raise statistical issues, particularly random
variation. When evaluating trends, it is vital to assess the
magnitude and direction along with the notation of statis-
tical significance, particularly for smaller subgroups.
Future Directions
This annual report brings attention to the growing burden
of liver cancer in the United States. Most cases of liver
cancer are preventable.104 One of the most important and
preventable risk factors for liver cancer is chronic HCV
infection; yet, despite this knowledge, new HCV infec-
tions continue to occur.28,105 Prevention strategies aimed
at reducing the frequency of behaviors that increase the
risk of HCV transmission can be effective in reducing
HCV infection. Early diagnosis of HCV infection with
referral to treatment services can decrease a patient’s risk
for subsequent health outcomes, such as liver cancer, and
can decrease transmission of the virus to others. Cures of
HCV infection are associated with a 75% reduction in the
risk of liver cancer.106,107 In addition to appropriate med-
ical care and management for HCV infection, other strat-
egies to reduce the burden of liver cancer in the United
States include promoting hepatitis B vaccination strat-
egies; reducing unhealthy behaviors, such as tobacco use
and excessive alcohol use; and reducing obesity by pro-
moting healthy eating and physical activity. Furthermore,
improvements in the public health surveillance of both
acute and chronic viral hepatitis infections can help to
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better monitor the incidence and prevalence of infections
and to evaluate interventions.
Although increases in liver cancer incidence and
mortality are concerning, the continuing decline in cancer
death rates for all sites combined and for the leading can-
cer sites overall demonstrate progress in cancer prevention
and control in general. However, even if incidence rates
remain stable or decline, the number of individuals diag-
nosed with cancer and living after a diagnosis will con-
tinue to rise because of improvements in treatment and
because of population growth and aging.108 Thus, pri-
mary, secondary, and tertiary cancer prevention efforts at
the patient and population-based levels are important.
Continued focus on primary prevention efforts to reduce
or eradicate risk factors before cancer occurs is critical.
Cancer is a heterogeneous disease, and each cancer site has
a unique set of risk factors. However, many modifiable
cancer risk factors contribute to the burden of many can-
cer sites, including tobacco use, excess alcohol consump-
tion, poor diet, excess body weight, and physical
inactivity.109,110 Reductions in these unhealthy behaviors
and improvements in healthy lifestyles over time can
reduce the burden of cancer.
Although many cancer risk factors are modifiable or
avoidable, many are not. Much of the morbidity and mor-
tality associated with cancer can be prevented by detecting
the disease at an early stage, when treatment is more effec-
tive.30,57,111,112 On the basis of systematic reviews of the
net benefits and harms of screening, the USPSTF cur-
rently recommends population-based screening for colo-
rectal, female breast, and cervical cancers among persons
at average risk of developing these cancers and for lung
cancer among persons at high-risk on the basis of their cig-
arette smoking history and age.113 Regardless of how the
cancer is diagnosed, reducing morbidity and mortality
associated with the disease depends on timely and appro-
priate treatment. Removing barriers to receipt of appro-
priate cancer screening and treatment, including financial
barriers, is crucial.114 Programs like the CDC’s National
Breast and Cervical Cancer Early Detection Program66
and the CDC’s Colorectal Cancer Control Program63 can
provide needed services, such as free or low-cost early can-
cer detection examinations, patient navigation services,
and treatment.
For individuals diagnosed with cancer (cancer survi-
vors), methods to mitigate the negative effects of a diagno-
sis and its treatment and to prevent the recurrence of
cancer are also critical. Cancer survivors often face long-
term adverse physical, psychosocial, and financial effects
from their cancer diagnosis and treatment.115-121 In addi-
tion, cancer survivors are at an increased risk of subse-
quent primary cancers.122,123 Cancer can have a long-
term impact on the health and well being of the cancer
survivor. This has important implications for ongoing
preventive care for all cancers and comorbid conditions.
Finally, disease surveillance is essential to the prac-
tice of public health for guiding prevention and control
activities, monitoring trends, and evaluating out-
comes.124,125 Information obtained from cancer inci-
dence registries and vital statistics systems provide
decision makers with vital information necessary to lead
and manage effective cancer prevention and control pro-
grams. Cancer registry systems are among the most so-
phisticated and standardized surveillance systems in the
United States. Routine monitoring of cancer incidence
and mortality helps to evaluate outcomes of public health-
oriented cancer prevention efforts and to identify areas
and populations with high cancer incidence or mortality
rates that can benefit from targeted interventions to pro-
mote healthy environments and behaviors.
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SUPPORTING FIGURE 1. Age-specific incidence ratesa and 95% confidence intervals for 
2008–2012 of liver and intrahepatic bile duct cancer by race or ethnicity for areas in the United 
States with high-quality incidence data.b 
 
Abbreviations: NH, Non-Hispanic; AI/AN, American Indian/Alaska Native; API, Asian/Pacific 
Islander; IHS, Indian Health Service; CHSDA, Contract Health Services Delivery Area. 
a Rates are per 100,000 persons and were age-adjusted to the 2000 US standard population (19 
age groups: ages <1 year, 1–4 years, 5–9 years, …, 80–84 years, ≥85 years; Census publication 
p25–1130; US Bureau of the Census, Current Population Reports, p25–1130. Washington, DC: 
US Government Printing Office, 2000).  
b Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End 
Results areas reported by North American Association of Central Cancer Registries as meeting 
high-quality incidence data standards for the specified time. 2008–2012 rates for NH whites, NH 
blacks, NH AI/AN (CHSDA 2012 counties), NH API, Hispanic (48 states):  Alabama, Alaska, 
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, 
Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, 
Massachusetts, Michigan, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New 
Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, 
Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, 
Virginia, Washington, West Virginia, Wisconsin, Wyoming. 
 
